prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Laboratory automation is the use of automated equipment, robotics and software to perform or coordinate processes in a laboratory with reduced human intervention. Automation can range from individual instruments that perform specific tasks to integrated systems that coordinate multiple stages of an experimental or analytical workflow. It is used in areas including clinical testing, high-throughput screening, biotechnology, chemistry and materials science. Laboratory automation can increase experimental throughput, reduce repetitive manual work, and improve the consistency of laboratory processes. Automated systems may include liquid-handling equipment, autosamplers, analytical instruments, robotic workstations, sample-transport systems and software for controlling instruments and coordinating workflows. More recently, laboratory automation has been combined with algorithmic experimental planning in self-driving laboratories and other autonomous laboratory systems. These systems use results from automated experiments to select subsequent experiments, creating a closed-loop process in which experimental execution, measurement, analysis and planning are integrated.
This advance enables the enantioselective construction of three-dimensional, sp³-rich molecules used in drug discovery and total synthesis. Sulfonyl hydrazides are commercially available as reagent feedstock.
MNs have been diverged into different forms, including Dermapen and Dermarollers. Dermarollers are hand-held rollers equipped with a total of 192 solid steel micro-sized needles arranged into 24 arrays, lengths ranging from 0.5-1.5mm. With the growing popularity of microneedling, MNs have also been commodified into home care Dermarollers, which are similar to medical dermarollers, except that the needles are shorter (0.15mm). This is a more budget-friendly device that allows individuals to perform microneedling at home.
== Function == GPVI is a 58-kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. Upon injury to the vessel wall and subsequent damage to the endothelial lining, exposure of the subendothelial matrix to blood flow results in deposition of platelets. Collagen fibers are the most thrombogenic macromolecular components of the extracellular matrix, with collagen types I, III, and VI being the major forms found in blood vessels. Platelet interaction with collagen occurs as a 2-step procedure: (1) the initial adhesion to collagen is followed by (2) an activation step leading to platelet secretion, recruitment of additional platelets, and aggregation. In physiologic conditions, the resulting platelet plug is the initial hemostatic event limiting blood loss. However, exposure of collagen after rupture of atherosclerotic plaques is a major stimulus of thrombus formation associated with myocardial infarction or stroke. Complete or partial deficiency of GPVI in humans is a rare condition presenting as a mild bleeding disorder.
=== Fish glue === Fish glue is made from the bones or tissues of fish. Isinglass is made specifically from the swim bladders, and is collagen-based. Fish glues were used in Ancient Egypt and Classical Antiquity in the Mediterranean; they continued to be used in Europe in Late Antiquity and the Medieval period, and are still used in niche applications today. It is brittle when dried, so it has sometimes been mixed with plasticizers such as molasses and honey. It was used in art, book binding, woodworking, lutherie, and for gluing paper and bone.
Sources: en.wikipedia.org
After 137Cs and 90Sr have decayed to low levels, the bulk of radioactivity from spent fuel come not from fission products but actinides, notably plutonium-239 (half-life 24 ka), plutonium-240 (6.56 ka), americium-241 (432 years), americium-243 (7.37 ka), curium-245 (8.50 ka), and curium-246 (4.73 ka). These can be recovered by nuclear reprocessing (either before or after most 137Cs and 90Sr decay) and fissioned, offering the possibility of greatly reducing waste radioactivity in the time scale of about 103 to 105 years. 239Pu is usable as fuel in existing thermal reactors, but some minor actinides like 241Am, as well as the non-fissile and less-fertile isotope plutonium-242, are better destroyed in fast reactors, accelerator-driven subcritical reactors, or fusion reactors. Americium-241 has some industrial applications and is used in smoke detectors and is thus often separated from waste as it fetches a price that makes such separation economic.
== Method of action == Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Shōyu is officially divided into five main types by the JAS (Japanese Agricultural Standard) depending on differences in their ingredients and method of production. These types are koikuchi, usukuchi, tamari, saishikomi, and shiro. Most, but not all, Japanese soy sauces include wheat as a primary ingredient, which tends to give them a slightly sweeter taste than their Chinese counterparts. They also tend towards an alcoholic sherry-like flavor, sometimes enhanced by the addition of small amounts of alcohol as a natural preservative. The widely varying flavors of these soy sauces are not always interchangeable, so some recipes only call for one type or the other, much as a white wine cannot replace a red's flavor or beef stock does not make the same results as chicken stock. Some soy sauces made in the Japanese way or styled after them contain about 50% wheat.
The service-entry deadline of summer 1980, announced by Minister of Civil Aviation Boris Bugayev in 1977 had passed, however, and the Il-86 missed the Moscow Olympics in the summer of 1980. Overall development of the Il-86 occupied over a decade. The length of this period was due to the sensitivity of the airliner's configuration, problems with its powerplant, prolonged avionics development and the low priority of civil as opposed to military aircraft. In its earlier stages, the Il-86 programme was also held back by hopes of US airliner imports. Certificating the Il-86 to the very demanding set of Soviet and Comecon standards called NLGS-2 also delayed progress; it was the first Soviet aircraft to undergo a full certification programme since certification was introduced in the USSR in 1967 and became mandatory five years later.
Sources: en.wikipedia.org
=== Biological characteristics === Like other aptamers, L-RNA aptamers are able to bind molecules such as peptides, proteins, and substances of low molecular weight. The affinity of L-RNA aptamers to their target molecules often lies in the pico to nanomolar range and is thus comparable to antibodies. L-RNA aptamers themselves have low antigenicity. In contrast to other aptamers, L-RNA aptamers have high stability in blood serum, since they are less susceptible to be cleaved hydrolytically by enzymes. They are excreted by the kidneys in a short time due to their low molar mass (which is below the renal threshold). L-RNA aptamers modified with a higher molar mass, such as PEGylated L-RNA aptamers, show a prolonged plasma half-life.
=== Fan works === The use of sandbox applications like Garry's Mod have allowed for Combine non-player characters to be used in a variety of webcomics and machinima productions. In one webcomic, Concerned, the Combine are portrayed as a highly bureaucratic and often inept organization. One issue shows a Civil Protection briefing for attempting to capture the comic's protagonist Gordon Frohman, in which officers are instructed to cluster around explosive barrels, seek cover on unstable structures and rappel down from bridges in front of fast moving vehicles. In another example, the machinima series Combine Nation follows Civil Protection officers in a similar style to police procedural documentaries. Other media portray the Combine with more serious overtones, such as the live-action video The Combine Interview, which parodies an interview with Tom Cruise discussing Scientology. The video, described by both Joystiq and Kotaku as "creepy", instead presents an interview with a Civil Protection officer discussing the Combine's rule of Earth, adapting Cruise's words to fit the Combine theme. PC Gamer UK noted that "the suggestion, of course, is that Scientology's purpose or self-image in some way resembles that of the homogenizing intergalactic murderous alien collective".
Rl = Xwαl/wRw + (1 − Xw)αl/sRs, where Rl, Rw, and Rs are the DHRs of lipids, water, and substrates, respectively. Xw is the mole fraction of lipid H derived from external water, whereas αl/w and αl/s denote the net isotopic fractionations associated with uptake and utilization of water and substrate hydrogen, respectively. For phototrophs, Rl is calculated assuming that Xw = 1. The isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids. The isotopic fractionation between lipids and water (αl/w) is 0.95 for fatty acids and 0.85 for isoprenoid lipids. For plants and algae, the isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.